

Contents

People	Officers of the Convention	4434
	Board of Trustees	4484
	General Committee of Revision	4484
	Executive Committee of Revision	4486
	USP Nomenclature Committee	4486
	Division of Standards Development Executive Committee and Subcommittees	4486
	USP Reference Standards Committee	4486
	USP-FDA Joint Committee on Bioequivalence	4487
	USP-FDA Antibiotic Monograph Subcommittee	4487
	Division of Standards Development Panels	4487
Admissions IMPORTANT—Annotated ist of Changes and Additions	New Monographs Appearing in This Supplement	4489
	Changes in Official Titles Appearing in This Supplement	4490
	Monographs, General Chapters, Reagents, and Tables Affected by Changes Appearing in This Supplement	4492
Notices	Introduction	4498
Monographs, USP	Official Monographs for USP 23	4501
General	General Tests and Assays	4623
	General Information	4674
Reagents	Reagents, Indicators, and Solutions	4679
Tables	Description and Relative Solubility of USP and NF Articles	4681
Nutritional Supplements	Official Monographs for USP 23	4684
	General Chapters—General Tests and Assays	4696
NF	Official Monographs for NF 18	4698
Index	Changes to Combined Index to USP 23 and NF 18	4713
	Cumulative Index to Ninth Supplement	4714

Moving ?

Our subscribers' records and publication labels are computer-generated for efficient service. When you change your address and give us 30-days notice together with a recent address label, you assure our mailing to the proper address. Please send your new address and your latest label, or an exact copy of it, to: USPC, Customer Service Dept., P.O. Box 560, Williston, VT 05495-0560.

Contents

People	Officers of the Convention	4434
	Board of Trustees	4484
	General Committee of Revision	4484
	Executive Committee of Revision	4486
	USP Nomenclature Committee	4486
	Division of Standards Development Executive Committee and Subcommittees	4486
	USP Reference Standards Committee	4486
	USP-FDA Joint Committee on Bioequivalence	4487
	USP-FDA Antibiotic Monograph Subcommittee	4487
	Division of Standards Development Panels	4487
Admissions IMPORTANT—Annotated ist of Changes and Additions	New Monographs Appearing in This Supplement	4489
	Changes in Official Titles Appearing in This Supplement	4490
	Monographs, General Chapters, Reagents, and Tables Affected by Changes Appearing in This Supplement	4492
Notices	Introduction	4498
Monographs, USP	Official Monographs for USP 23	4501
General	General Tests and Assays	4623
	General Information	4674
Reagents	Reagents, Indicators, and Solutions	4679
Tables	Description and Relative Solubility of USP and NF Articles	4681
Nutritional Supplements	Official Monographs for USP 23	4684
	General Chapters—General Tests and Assays	4696
NF	Official Monographs for NF 18	4698
Index	Changes to Combined Index to USP 23 and NF 18	4713
	Cumulative Index to Ninth Supplement	4714

Moving ?

Our subscribers' records and publication labels are computer-generated for efficient service. When you change your address and give us 30-days notice together with a recent address label, you assure our mailing to the proper address. Please send your new address and your latest label, or an exact copy of it, to: USPC, Customer Service Dept., P.O. Box 560, Williston, VT 05495-0560.

People

United States Pharmacopeial Convention

Officers (1995-2000)

Jane E. Henney, M.D.
President
Albuquerque, NM
John T. Fay, Jr., Ph.D.
Treasurer
San Clemente, CA
Mark Novitch, M.D.
Past President
Washington, DC
Jerome A. Halperin
Secretary
Rockville, MD

Board of Trustees (1995-2000)

Jordan L. Cohen, Ph.D.¹
Chair
Lexington, KY
Edwin D. Bransome, Jr., M.D.²
Augusta, GA
William H. Campbell, Ph.D.¹
Chapel Hill, NC
John T. Fay, Jr., Ph.D.
ex officio
San Clemente, CA
Jean Paul Gagnon, Ph.D.²
Kansas City, MO
Jane E. Henney, M.D.
ex officio
Albuquerque, NM
Edward L. Langston, R.Ph., M.D.³
Rock Island, IL
Joseph A. Mollica, Ph.D.²
Princeton, NJ
Grace Powers Monaco, J.D.⁴
Burgess, VA

Mark Novitch, M.D.
ex officio
Washington, DC
Edward Zalta, M.D.⁵
Newport Beach, CA

General Committee of Revision 1995-2000

Jerome A. Halperin,
Executive Vice President, USPC.
12601 Twinbrook Parkway
Rockville, MD 20852
Chair

Lee T. Grady, Ph.D.²
*Vice President and Director
of Standards Development*

Keith W. Johnson¹
*Vice President and Director
of Information Development*

Lloyd V. Allen, Jr., Ph.D.
Oklahoma City, OK

Jerry R. Allison, Ph.D.* (1995)
New Brunswick, NJ

Thomas J. Ambrosio, Ph.D.
Kenilworth, NJ

Ann B. Amerson, Pharm.D.
Lexington, KY

Gordon L. Amidon, Ph.D.
Ann Arbor, MI

Gregory E. Amidon, Ph.D.
Kalamazoo, MI

Henry L. Avallone
Titusville, NJ

Larry L. Augsburger, Ph.D.
Baltimore, MD

Leonard C. Bailey, Ph.D.
Piscataway, NJ

Jorge R. Barrio, Ph.D.
Los Angeles, CA

Gregory B. Bennett, Ph.D., M.B.A.
East Hanover, NJ

Terrence F. Blaschke, M.D.
Stanford, CA

Judy P. Boehiert, Ph.D.
Park Ridge, NJ

James C. Boylan, Ph.D.
Abbott Park, IL

R. Edward Branson, Ph.D.
Brookville, MD

William H. Briner, Capt.
Durham, NC

Harry G. Brittain, Ph.D.
Milford, NJ

Paul M. Bummer, Ph.D. R.Ph.
Lexington, KY

Stephen R. Byrn, Ph.D.
West Lafayette, IN

Peter R. Byron, Ph.D.
Richmond, VA

Ronald J. Cailhan, Ph.D.
Boston, MA

Herbert S. Carlin, D.Sc.
Califon, NJ

Culley C. Carson, M.D.
Chapel Hill, NC

Lester Chafetz, Ph.D.
Kansas City, MO

Yie W. Chien, Ph.D.
Piscataway, NJ

Henry M. Chilton, Pharm.D.
Winston-Salem, NC

Zak T. Chowhan, Ph.D.
Hunt Valley, MD

Sebastian G. Ciancio, D.D.S.
Buffalo, NY

Patricia E. Cole, Ph.D., M.D.
Stony Brook, NY

David S. Cooper, M.D.
Baltimore, MD

Murray S. Cooper, Ph.D.
Islamorada, FL

William A. Craig, M.D.
Madison, WI

Stephanie Y. Crawford, Ph.D.
Chicago, IL

Edward M. Croom, Ph.D.
University, MS

Ian E. Davidson, Ph.D., M.B.A.
Kansas City, MO

Leon Ellenbogen, Ph.D.
Wayne, NJ

Hans Fisher, Ph.D.
New Brunswick, NJ

Edward A. Fitzgerald, Ph.D.
Rockville, MD

Everett Flanigan, Ph.D.
Kankakee, IL

Thomas S. Foster, Pharm.D.
Lexington, KY

C. David Fox, Ph.D.
Rouses Point, NY

Sylvan G. Frank, Ph.D.
Columbus, OH

¹ Representing pharmacy.

² At large.

³ Representing medicine.

⁴ Public member.

⁵ 12601 Twinbrook Parkway

Rockville, MD 20852.

* Deceased.

- David O. Freedman, M.D.
Birmingham, AL
- Joseph F. Gallelli, Ph.D.
Bethesda, MD
- Barry D. Garfinkle, Ph.D.
West Point, PA
- Robert L. Garnick, Ph.D.
So. San Francisco, CA
- John Christian Gillin, M.D.
San Diego, CA
- Douglas D. Glover, R.Ph., M.D.
Morgantown, WV
- Alan M. Goldberg, Ph.D.
Baltimore, MD
- Dennis K.J. Gorecki, Ph.D.
Saskatoon, Saskatchewan, CANADA
- Robert M. Guthrie, M.D.
Columbus, OH
- Samir A. Hanna, Ph.D.
Lawrenceville, NJ
- Stanley L. Hem, Ph.D.
West Lafayette, IN
- Evelyn V. Hess, M.D., F.A.C.P.,
M.A.C.R.
Cincinnati, OH
- Joy Hochstadt, Ph.D.
New York, NY
- Richard D. Johnson, Ph.D., Pharm.D.
Kansas City, MO
- H. Thomas Karnes, Ph.D.
Richmond, VA
- David B. Katague, Ph.D.
Rockville, MD
- Rosalyn C. King, Pharm.D., M.P.H.
Silver Spring, MD
- Gordon L. Klein, M.D., M.P.H.
Galveston, TX
- Harvey G. Klein, M.D.
Bethesda, MD
- Joseph E. Knapp, Ph.D.
Pittsburgh, PA
- Michael S. Korczynski, Ph.D.
Baltimore, MD
- Helen F. Krause, M.D.
Pittsburgh, PA
- Paul Kucera, Ph.D.
Pearl River, NY
- Pauline M. Lacroix, M.S.
Ottawa, Ontario, CANADA
- Vernon C. Langston, D.V.M., Ph.D.
Mississippi State, MS
- Thomas P. Layloff, Ph.D.
St. Louis, MO
- Patricia D. Leinbach, Ph.D.
Rockville, MD
- John W. Levchuk, Ph.D.
Rockville, MD
- Robert D. Lindeman, M.D.
Albuquerque, NM
- Charles H. Lochmüller, Ph.D.
Durham, NC
- Hugh E. Lockhart, Ph.D.
East Lansing, MI
- Edward G. Lovering, Ph.D.
Nepean, Ontario, CANADA
- Catherine M. MacLeod, M.D.
Chicago, IL
- Carol S. Marcus, Ph.D., M.D.
Torrance, CA
- Joan C. May, Ph.D.
Rockville, MD
- Michael Mayersohn, Ph.D.
Tucson, AZ
- Keith M. McEriane, Ph.D.
Vancouver, BC, CANADA
- Thomas Medwick, Ph.D.
Piscataway, NJ
- Robert F. Morrissey, Ph.D.
New Brunswick, NJ
- Terry E. Munson
Fairfax, VA
- Steven L. Nail, Ph.D.
West Lafayette, IN
- Harold S. Nelson, M.D.
Denver, CO
- David W. Newton, Ph.D.
Winchester, VA
- Sharon J. Northup, Ph.D., M.B.A.
Deerfield, IL
- Samuel W. Page, Ph.D.
Washington, DC
- Garnet E. Peck, Ph.D.
West Lafayette, IN
- Robert V. Petersen, Ph.D.
Salt Lake City, UT
- Rosemary C. Polomano, Ph.D., M.S.N.,
R.N.
Philadelphia, PA
- Ronald E. Reid, Ph.D.
Vancouver, BC, CANADA
- Thomas P. Reinders, Pharm.D.
Richmond, VA
- Christopher T. Rhodes, Ph.D.
Kingston, RI
- Jim E. Riviere, D.V.M., Ph.D.
Raleigh, NC
- George A. Robertson, Ph.D.
Frederick, MD
- Joseph R. Robinson, Ph.D.
Madison, WI
- Lary A. Robinson, M.D.
Tampa, FL
- Harold N. Rode, Ph.D.
Ottawa, Ontario, CANADA
- Dan M. Roden, M.D.
Nashville, TN
- David B. Roll, Ph.D.
Salt Lake City, UT
- Thomas W. Rossanske, Ph.D.
Kansas City, MO
- Theodore J. Roseman, Ph.D.
Round Lake, IL
- Peter C. Ruenitz, Ph.D.
Athens, GA
- Sally S. Seaver, Ph.D.
Concord, MA
- Gordon D. Schiff, M.D.
Chicago, IL
- Paul L. Schiff, Jr., Ph.D.
Pittsburgh, PA
- Ralph F. Shangraw, Ph.D.* (1995-1998)
Baltimore, MD
- Eli Shefter, Ph.D.
La Jolla, CA
- Eric B. Sheinin, Ph.D.
Rockville, MD
- Robert L. Siegle, M.D.
San Antonio, TX
- Edward B. Silberstein, M.D.
Cincinnati, OH
- Marilyn Dix Smith, Ph.D.
Princeton, NJ
- Emil J. Staba, Ph.D.
Minneapolis, MN
- Thomas E. Starzl, M.D., Ph.D.
Pittsburgh, PA
- Robert S. Stern, M.D.
Boston, MA
- James T. Stewart, Ph.D.
Athens, GA
- Scott V.W. Sutton, Ph.D.
Fort Worth, TX
- Dennis P. Swanson, M.S.
Pittsburgh, PA
- Henry S.I. Tan, Ph.D.
Cincinnati, OH
- Thomas D. Thomson, Ph.D., V.M.D.
Greenfield, IN
- Clarence T. Ueda, Pharm.D., Ph.D.
Omaha, NE
- Huib J.M. van de Donk, Ph.D.
Bilthoven, THE NETHERLANDS
- Stanley van den Noort, M.D.
Irvine, CA
- Joseph C. Veltri, Pharm.D.
Salt Lake City, UT
- Robert E. Vestal, M.D.
Boise, ID
- Irving W. Wainer, Ph.D.
Washington, DC
- Philip D. Walsom, M.D.
Columbus, OH
- Elliott T. Weisman
Philadelphia, PA
- Paul F. White, Ph.D., M.D.
Dallas, TX
- Richard J. Whitley, M.D.
Birmingham, AL
- Robert G. Wolfangel, Ph.D.
St. Louis, MO
- Manfred E. Wolff, Ph.D.
Laguna Beach, CA
- Marie Linda A. Workman, Ph.D., R.N.
Cleveland, OH
- Wesley E. Workman, Ph.D.
St. Louis, MO
- Timothy J. Wozniak, Ph.D.
Indianapolis, IN
- Dale Eric Wurster, Ph.D.
Iowa City, IA
- John W. Yarbrow, M.D., Ph.D.
Springfield, IL
- Lynn C. Yeoman, Ph.D.
Houston, TX
- Thom J. Zimmerman, M.D., Ph.D.
Louisville, KY

Executive Committee of Revision

JEROME A. HALPERIN, *Chair*

Lester Chafetz, Ph.D.; Joseph F. Gallelli, Ph.D.; Gordon L. Klein, M.D., M.P.H.; Robert D. Lindeman, M.D.; Carol S. Marcus, Ph.D., M.D.; Joseph R. Robinson, Ph.D.

USP Nomenclature Committee

HERBERT S. CARLIN, D.Sc., *Chair*

William M. Heller, Ph.D., *Consultant/Advisor*

Ann B. Amerson, Pharm.D.; Lester Chafetz, Ph.D.; Stephanie Y. Crawford, Ph.D.; Everett Flanagan, Ph.D.; Douglas D. Glover, R.Ph., M.D.; Richard D. Johnson, Ph.D., Pharm.D.; Edward G. Lovering, Ph.D.; Rosemary C. Polomano, Ph.D., M.S.N., R.N.; Thomas P. Reinders, Pharm.D.; Eric B. Sheinin, Ph.D.; Thomas D. Thomson, Ph.D., V.M.D.; Philip D. Watson, M.D.

Division of Standards Development Executive Committee

THOMAS P. LAYLOFF, Ph.D., *Chair*

Gregory E. Amidon, Ph.D.; Judy P. Boehlert, Ph.D.; James C. Boylan, Ph.D.; William H. Briner, Capt.; Herbert S. Carlin, D.Sc.; Zak T. Chowhan, Ph.D.; Everett Flanagan, Ph.D.; Thomas S. Foster, Pharm.D.; Robert L. Garnick, Ph.D.; Dennis K.J. Gorecki, Ph.D.; Stanley L. Hem, Ph.D.; Joseph E. Knapp, Ph.D.; Paul Kucera, Ph.D.; Thomas P. Layloff, Ph.D.; Edward G. Lovering, Ph.D.; Thomas Medwick, Ph.D.; Sharon J. Northup, Ph.D., M.B.A.; Ralph F. Shangraw, Ph.D.* (1995–1998); James T. Stewart, Ph.D.; Henry S.I. Tan, Ph.D.; Elliott T. Weisman

Division of Standards Development Subcommittees

ANT. Subcommittee on Antibiotics

HENRY S.I. TAN, Ph.D., *Chair*

Samir A. Hanna, Ph.D.; David B. Katague, Ph.D.; Paul Kucera, Ph.D.; Keith M. McErlane, Ph.D.; Jim E. Riviere, D.V.M., Ph.D.; Eli Shefter, Ph.D.; Eric B. Sheinin, Ph.D.; Thomas D. Thomson, Ph.D., V.M.D.

BBV. Subcommittee on Biopolymers, Bioproducts, and Vaccines

EVERETT FLANIGAN, Ph.D., *Chair*

Yie W. Chien, Ph.D.; Murray S. Copper, Ph.D.; Barry D. Garfinkle, Ph.D.; George A. Robertson, Ph.D.; Huib J.M. van de Donk, Ph.D.; Richard J. Whitley, M.D.; Manfred E. Wolff, Ph.D.

BGT. Subcommittee on Biotechnology and Gene Therapy

ROBERT L. GARNICK, Ph.D., *Chair*

R. Edward Branson, Ph.D.; Paul M. Bummer, Ph.D., R.Ph.; Patricia E. Cole, Ph.D., M.D.; Joseph F. Gallelli, Ph.D.; Harold N. Rode, Ph.D.; Sally S. Seaver, Ph.D.; Wesley E. Workman, Ph.D.; Lynn C. Yeoman, Ph.D.

CH1. Subcommittee on Chemistry 1

STANLEY L. HEM, Ph.D., *Chair*

Lloyd V. Allen, Jr., Ph.D.; H. Thomas Karnes, Ph.D.; Patricia D. Leinbach, Ph.D.; Joan C. May, Ph.D.; Thomas Medwick, Ph.D.; Thomas D. Thomson, Ph.D., V.M.D.

CH2. Subcommittee on Chemistry 2

DENNIS K.J. GORECKI, Ph.D., *Chair*

Gregory B. Bennett, Ph.D., M.B.A.; Lester Chafetz, Ph.D.; H. Thomas Karnes, Ph.D.; Charles H. Lochmüller, Ph.D.; Eli Shefter, Ph.D.; Marilyn Dix Smith, Ph.D.

CH3. Subcommittee on Chemistry 3

JUDY P. BOEHLERT, Ph.D., *Chair*

Stephen R. Byrn, Ph.D.; Ian E. Davidson, Ph.D., M.B.A.; Thomas P. Layloff, Ph.D.; Keith M. McErlane, Ph.D.; Peter C. Ruenitz, Ph.D.; Irving W. Wainer, Ph.D.

CH4. Subcommittee on Chemistry 4

ELLIOTT T. WEISMAN, *Chair*

Harry G. Brittain, Ph.D.; Pauline M. Lacroix, M.S.; Thomas W. Rosanske, Ph.D.; Eric B. Sheinin, Ph.D.; Timothy J. Wozniak, Ph.D.

CH5. Subcommittee on Chemistry 5

EDWARD G. LOVERING, Ph.D., *Chair*

Leonard C. Bailey, Ph.D.; Peter R. Byron, Ph.D.; Charles H. Lochmüller, Ph.D.; James T. Stewart, Ph.D.; Robert G. Wolfangel, Ph.D.; Manfred E. Wolff, Ph.D.; Wesley E. Workman, Ph.D.

DBA. Subcommittee on Dissolution and Bioavailability

THOMAS S. FOSTER, Pharm.D., *Chair*

Gordon L. Amidon, Ph.D.; Stephen R. Byrn, Ph.D.; Michael Mayersohn, Ph.D.; Christopher T. Rhodes, Ph.D.; Joseph R. Robinson, Ph.D.; Thomas W. Rosanske, Ph.D.; Theodore J. Roseman, Ph.D.; Eli Shefter, Ph.D.; Clarence T. Ueda, Pharm.D., Ph.D.

EX1. Subcommittee on Excipients—Monographs

ZAK T. CHOWHAN, Ph.D., *Chair*

Larry L. Augsburg, Ph.D.; Peter R. Byron, Ph.D.; C. David Fox, Ph.D.; Sylvan G. Frank, Ph.D.; Joan C. May, Ph.D.; Garnet E. Peck, Ph.D.; Ralph F. Shangraw, Ph.D.

EX2. Subcommittee on Excipients—Methods

GREGORY E. AMIDON, Ph.D., *Chair*

Larry L. Augsburg, Ph.D.; Harry G. Brittain, Ph.D.; Stephen R. Byrn, Ph.D.; C. David Fox, Ph.D.; Garnet E. Peck, Ph.D.; Dale E. Wurster, Ph.D.

GEN. Subcommittee on General Chapters

THOMAS P. LAYLOFF, Ph.D., *Chair*

Judy P. Boehlert, Ph.D.; Irving W. Wainer, Ph.D.

MCB. Subcommittee on Microbiology

JOSEPH E. KNAPP, Ph.D., *Chair*

Henry L. Avallone; Murray S. Cooper, Ph.D.; Edward A. Fitzgerald, Ph.D.; Barry D. Garfinkle, Ph.D.; Michael S. Korczynski, Ph.D.; John W. Levchuk, Ph.D.; Robert F. Morrissey, Ph.D.; Terry E. Munson; Steven L. Nail, Ph.D.; Scott V.W. Sutton, Ph.D.; Huib J.M. van de Donk, Ph.D.

MPI. Subcommittee on Multisource Products Issues

JAMES T. STEWART, Ph.D., *Chair*

NAT. Subcommittee on Natural Products

PAUL KUCERA, Ph.D., *Chair*

Edward M. Croom, Ph.D.; David B. Katague, Ph.D.; Edward G. Lovering, Ph.D.; Samuel W. Page, Ph.D.; Paul L. Schiff, Jr., Ph.D.; E. John Staba, Ph.D.

NDN. Subcommittee on Nonprescription Drugs and Nutritional Supplements

RALPH F. SHANGRAW, Ph.D., *Chair** (1995–1998)

Leon Ellenbogen, Ph.D.; Hans Fisher, Ph.D. (1995–1998); Dennis K.J. Gorecki, Ph.D.; Edward G. Lovering, Ph.D.; David B. Roll, Ph.D.

PSD. Subcommittee on Packaging, Storage, and DistributionTHOMAS MEDWICK, Ph.D., *Chair*

Lloyd V. Allen, Jr., Ph.D.; Thomas J. Ambrosio, Ph.D.; Larry L. Augsburger, Ph.D.; Leonard C. Bailey, Ph.D.; Zak T. Chowhan, Ph.D.; Hugh E. Lockhart, Ph.D.; David W. Newton, Ph.D.; Christopher T. Rhodes, Ph.D.

RAD. Subcommittee on RadiopharmaceuticalsWILLIAM H. BRINER, Capt., *Chair*

Jorge R. Barrio, Ph.D.; Ronald J. Callahan, Ph.D.; Henry M. Chilton, Pharm.D.; Edward B. Silberstein, M.D.; Dennis P. Swanson, M.S.

TBC. Subcommittee on Toxicity, Biocompatibility, and Cell CultureSHARON J. NORTUP, Ph.D., M.B.A., *Chair*

Thomas J. Ambrosio, Ph.D.; Alan M. Goldberg, Ph.D.; Joy Hochstadt, Ph.D.; Robert V. Petersen, Ph.D.; Ronald E. Reid, Ph.D.; Peter C. Ruenitz, Ph.D.; Marie Linda A. Workman, Ph.D.; R.N.

W&P. Subcommittee on Water and ParenteralsJAMES C. BOYLAN, Ph.D., *Chair*

Henry L. Avallone; Joseph F. Gallelli, Ph.D.; John W. Levchuk, Ph.D.; Terry E. Munson; Steven L. Nail, Ph.D.; David W. Newton, Ph.D.; Theodore J. Roseman, Ph.D.; Marie Linda A. Workman, Ph.D.; R.N.

USP Reference Standards CommitteeLEE T. GRADY, Ph.D., *Chair, ex officio*

Judy P. Boehlert, Ph.D.; Zak T. Chowhan, Ph.D.; Everett Flanagan, Ph.D.; Stanley L. Hem, Ph.D.; Thomas P. Layloff, Ph.D.; Edward G. Lovering, Ph.D.; Sharon J. Northup, Ph.D.

USP-FDA Joint Committee on BioequivalenceROBERT A. RIPPERS, *Chair*

Representing FDA, Rockville, MD:

Ramakant M. Mhatre, Ph.D.; Larry A. Ouderkirk; Robert A. Rippers

Representing USP, Rockville, MD:

Thomas S. Foster, Pharm.D.; Lee T. Grady, Ph.D.; Barbara B. Hubert; Lewis J. Leeson, Ph.D.

USP-FDA Antibiotic Monograph SubcommitteeWILLIAM W. WRIGHT, Ph.D., *Chair*

Representing FDA, Rockville, MD:

Peter Dionne; Katharine A. Freeman; James M. Timper, Jr., M.S.; Robert A. Rippers

Representing USP, Rockville, MD:

Roger Dabbah, Ph.D.; Lee T. Grady, Ph.D.; William W. Wright, Ph.D.

Division of Standards Development Panels**Advisory Panel on Analytical Methods for Nonprescription Drugs and Nutritional Supplements**RALPH F. SHANGRAW, Ph.D., *Chair*, (1995-1998) Baltimore MD:

Norman W. Atwater, Ph.D., Columbus, NJ; David M. Banske, Ph.D., Baltimore, MD; Frederick Bangert, Morrisville, NC; Ofelia Barretto, Buena Park, CA; Ira Berry, Union, NJ; Hemi Bhagwan, Ph.D., Nutley, NJ; Arthur D. Bond, Ph.D., Richmond, VA; Joy Joseph, San Fernando, CA; Marilyn Langley, Greenville, SC; Michael J. Lebeille, Ottawa, Ontario, CANADA; Herbert Letterman, Ph.D., New Providence, NJ; Jeffery L. Otto, Ph.D., Arvada, CO; Walter A. Schulze, Carson, CA; Michael Smets, Jr., Rockville, MD; Paula Jo Meyer Stout, Ph.D., Morgantown, WV; Margaret A. Targove, Ph.D., Princeton, NJ; William VanMeter, Allegan, MI; George L. Walker, Memphis, TN

Advisory Panel on Compendial Items: Storage, Shipment, and DistributionLEONARD C. BAILEY, Ph.D., *Chair*, Piscataway, NJ; Anthony Carfagno, Bethlehem, PA; Clyde R. Erskine, Newton Square, PA; Herbert Letterman, Ph.D., New Providence, NJ.**Advisory Panel on Gene and Cell Therapies**SALLY S. SEAVER, Ph.D., *Chair*, Concord, MA; Patricia E. Cole, Ph.D., M.D., Smithtown, NY; Steward Craig, Ph.D., Baltimore, MD; Gary C. DuMoulin, Ph.D., Cambridge, MA; Joyce D. Francis, Ph.D., Gaithersburg, MD; Joseph F. Gallelli, Ph.D., Bethesda, MD; Robert L. Garnick, Ph.D., So. San Francisco, CA; Richard D. Huhn, M.D., Bethesda, MD; Beth Hutchins, Ph.D., San Diego, CA; Ann Jakubowski, Ph.D., M.D., New York, NY; Andra Miller, Ph.D., Rockville, MD; Elizabeth J. Read, M.D., Bethesda, MD; Nancy C. Sajjadi, San Diego, CA; William E. Tente, Lincoln, RI; Joyce Frey Vasconcelis, Ph.D., Rockville, MD**Advisory Panel on Identification and Standardization of Natural Products**PAUL L. SCHIFF, JR., Ph.D., *Chair*, Pittsburgh, PA; Dennis V.C. Awang, Ph.D., Ottawa, Ontario, CANADA; Ezio Bombardelli, Ph.D., Milan, ITALY (1997-); Robert P. Borns, Ph.D., Rahway, NJ (1995-1996); Werner Busse, Ph.D., Karlsruhe, GERMANY (1997-); Horace G. Cutler, Ph.D., Atlanta, GA; Jonathan W. DeVries, Ph.D., Minneapolis, MN; Patrick Dunn, Carson, CA; Gary W. Elmer, Ph.D., Seattle, WA; Fran S. Ertl, Long Beach, CA (1996-); Patrick Hoffman, Ph.D., Hunt Valley, MD; Charles D. Hufford, Ph.D., University, MS; Michael Ihrig, Ph.D., Eschborn, GERMANY; A. Douglas Kinghorn, Ph.D., Chicago, IL; Nahid Mokhtari-Rejali, Ph.D., Rockville, MD; William Popin, M.S., American Fork, UT (1997-); Amaia Raman, Ph.D., London, UNITED KINGDOM; Rory P. Rimmel, Ph.D., Minneapolis, MN (1995-1997); Brent Roth, Park City, UT (1996-1997); Walter A. Schulze, Carson, CA (1996-1997); Sidney J. Stohs, Ph.D., Omaha, NE**Expert Advisory Panel on Pharmacy Compounding Practices**THOMAS MEDWICK, Ph.D., *Chair*, Piscataway, NJ; Martin Golden, *Consultant/Coordinator*, Smyrna, DE; Lloyd V. Allen, Jr., Ph.D., Oklahoma City, OK; Suggy Chrai, Ph.D., East Windsor, NJ; Mary Ann Kirkpatrick, Richmond, VA; David Liebman, Baltimore, MD; Paul Lofholm, Pharm.D., Kentfield, CA; James R. Morse, Tucson, AZ; J. Graham Nairn, Ph.D., Toronto, Ontario, CANADA; David W. Newton, Ph.D., Winchester, VA; Eveilyn D. Timmons, Paradise Valley, AZ**Advisory Panel on Microbiological Control and Process Validation**JOSEPH E. KNAPP, Ph.D., *Chair*, Pittsburgh, PA; James E. Akers, Ph.D., Kansas City, MO; Michael J. Akers, Ph.D., Indianapolis, IN; Wei-Wei Chang, Ph.D., Canton, MA; Richard LeVv, Ph.D., Bedford, MA; Tibor Matula, Ph.D., Ottawa, Ontario, CANADA; T.C. Soli, Ph.D., Greenville, NC; Marlys E. Weary, Mount Prospect, IL**Advisory Panel on Multisource Products**JAMES T. STEWART, Ph.D., *Chair*, Athens, GA; Edward M. Cohen, Ph.D., Carmel, NY; Peter Jeffs, Ottawa, Ontario, CANADA;

Lewis J. Leeson, Ph.D., Montville, NJ; Jeffery L. Otto, Ph.D., Arvada, CO; Sidney J. Smith, Ph.D., Markham, Ontario, CANADA; V. Subramanian, Ph.D., Northvale, NJ; Alice Till, Ph.D., Washington, DC; Vincent S. Venturella, Ph.D., Cedar Grove, NJ

Advisory Panel on Pharmacy Compounding General Chapter
MARY ANN KIRKPATRICK, Chair, Richmond, VA; Martin Golden, Consultant/Coordinator, Smyrna, DE; Suggy Chrai, Ph.D., East Windsor, NJ; Paul Lofholm, Pharm.D., Kenfield, CA; David W. Newton, Ph.D., Winchester, VA; Evelyn D. Timmons, Paradise Valley, AZ

Review Panel on Pharmacy Compounding Practices
THOMAS MEDWICK, Ph.D., Chair, Piscataway, NJ; Martin Golden, R.Ph. Consultant/Coordinator, Smyrna, DE; John W. Andrews, Winston Salem, NC; Daniel J. Jacob, Tucson, AZ; Nicholas G. Lordi, Ph.D., Piscataway, NJ; Timothy D. Moore, Columbus, OH; R. T. Moss, Jr., Florence, SC; Glynn G. Raymond, Ph.D., Albuquerque, NM; James A. Rogers, Ph.D., Edmonton, Alberta, CANADA; Howard L. Stark, Kansas City, MO; Judith E. Thompson, M.S., Madison, WI

Advisory Panel on Physical Test Methods
GREGORY E. AMIDON, Ph.D., Chair, Kalamazoo, MI; Michael S. Bergren, Ph.D., Kalamazoo, MI; David J.W. Grant, D.Phil., Minneapolis, MN; Keith Marshall, Ph.D., Brick, NJ; Shigeru Imai, Ph.D., Ohmiya-shi, Saitama, JAPAN

Advisory Panel on Polymeric Excipients
GARNET E. PECK, Ph.D., Chair, West Lafayette, IN; Tim D. Cabeika, Ph.D., Midland, MI; George Chen, Ph.D., Ridgerfield, CT; Bruno Hancock, Ph.D., Point-Claire-Dorval, Quebec, CANADA; James McGinity, Ph.D., Austin, TX; Kinam Park, Ph.D., West Lafayette, NJ; Stuart Porter, Ph.D., West Point, PA; Thomas A. Wheatley, Princeton, NJ; Richard Feigl, Ph.D., Kingsport, TN

Review Panel on Spanish Translation of USP Text
SOLOMON STAVCHANSKY, Ph.D., Chair, Austin, TX; Aquiles Arancibia, Ph.D., Santiago, CHILE; Enrique Ferer, Ph.D., Washington, DC; Regina Pezoa, Ph.D., Santiago, CHILE; Marcelo Vernengo, Ph.D., Buenos Aires, ARGENTINA

Admissions

New Monographs Appearing in This Supplement

USP 23

- | | |
|--|--|
| Capsules Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine,
Dextromethorphan, and Phenylpropanolamine | Dihydroxyacetone |
| Oral Solution Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine,
Dextromethorphan, and Phenylpropanolamine | Floxuridine for Injection |
| Capsules Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine,
Dextromethorphan, and Pseudoephedrine | Gentamicin Injection |
| Oral Solution Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine,
Dextromethorphan, and Pseudoephedrine | Hydralazine Hydrochloride Oral Solution |
| Tablets Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine,
Dextromethorphan, and Pseudoephedrine | Ifosfamide for Injection |
| Acetaminophen, Dextromethorphan Hydrobromide, Doxylamine
Succinate, and Pseudoephedrine Hydrochloride Oral
Solution | Indocyanine Green for Injection |
| Acetaminophen, Diphenhydramine Hydrochloride, and
Pseudoephedrine Hydrochloride Tablets | Indomethacin for Injection |
| Acyclovir Capsules | Ioxilan |
| Acyclovir for Injection | Ioxilan Injection |
| Acyclovir Oral Suspension | Kanamycin Injection |
| Acyclovir Tablets | Levocarnitine Injection |
| Albendazole Tablets | Lincomycin Injection |
| Altretamine | Magnesium Carbonate and Citric Acid for Oral Solution |
| Altretamine Capsules | Magnesium Citrate for Oral Solution |
| Astemizole | Methicillin Sodium |
| Calcium and Magnesium Carbonates Oral Suspension | Methicillin for Injection |
| Chloramphenicol Sodium Succinate | Mezlocillin Sodium |
| Chloramphenicol Sodium Succinate for Injection | Mezlocillin for Injection |
| Chlorpheniramine Maleate and Pseudoephedrine Hydrochloride
Oral Solution | Minocycline for Injection |
| Cholecalciferol Solution | Minoxidil Topical Solution |
| Clindamycin Injection | Naltrexone Hydrochloride |
| Clindamycin for Injection | Naltrexone Hydrochloride Tablets |
| Cocaine and Tetracaine Hydrochlorides and Epinephrine
Topical Solution | Narasin Granular |
| Colistimethate Sodium | Narasin Premix |
| Colistimethate for Injection | Oxacillin Injection |
| Cytarabine for Injection | Oxacillin for Injection |
| Dexbrompheniramine Maleate and Pseudoephedrine Sulfate
Oral Solution | Oxytetracycline for Injection |
| Dihydrostreptomycin Injection | Penicillin G Sodium |
| | Phenylpropanolamine Hydrochloride Capsules |
| | Phenylpropanolamine Hydrochloride Oral Solution |
| | Phenylpropanolamine Hydrochloride Tablets |
| | Pseudoephedrine Hydrochloride Extended-release Tablets |
| | Rifampin Oral Suspension |
| | Rimexolone |
| | Rimexolone Ophthalmic Suspension |
| | Roxarsone |
| | Selenomethionine |
| | Simvastatin Tablets |
| | Sodium Hypochlorite Topical Solution |
| | Succinylcholine Chloride for Injection |
| | Technetium Tc 99m Tetrofosmin Injection |
| | Tetracaine Hydrochloride for Injection |
| | Tiletamine Hydrochloride |
| | Tiletamine and Zolazepam for Injection |
| | Tolbutamide for Injection |
| | Triclosan |
| | Urea for Injection |
| | Zolazepam Hydrochloride |

NF 18

Betadex
Cellulose
Chamomile
Feverfew
Powdered Feverfew
Ginkgo
Oriental Ginseng

Powdered Oriental Ginseng
Hypromellose Phthalate
Lactitol
St. John's Wort
Powdered St. John's Wort
Saw Palmetto
Vitamin E Polyethylene Glycol Succinate

Changes in Official Titles Appearing in This Supplement

The following title changes are official November 15, 1998:

USP 23 New Title

USP 23 Former Title

Clindamycin Phosphate
Clindamycin Injection
Clindamycin for Injection
Colistimethate Sodium
Colistimethate for Injection
Cytarabine
Cytarabine for Injection
Dihydrostreptomycin Sulfate
Dihydrostreptomycin Injection
Ifosfamide
Ifosfamide for Injection
Indocyanine Green
Indocyanine Green for Injection
Indomethacin Sodium
Indomethacin for Injection
Kanamycin Sulfate
Kanamycin Injection
Lincomycin Hydrochloride
Lincomycin Injection
Methicillin Sodium
Methicillin for Injection
Mezlocillin Sodium
Mezlocillin for Injection
Minocycline Hydrochloride
Minocycline for Injection
Oxacillin Sodium
Oxacillin Injection
Oxacillin for Injection
Oxytetracycline
Oxytetracycline Hydrochloride
Oxytetracycline for Injection
Penicillin G Potassium
Penicillin G Potassium for Injection
Penicillin G Sodium
Penicillin G Sodium for Injection

Sterile Clindamycin Phosphate
Clindamycin Phosphate Injection
Sterile Clindamycin Phosphate
Sterile Colistimethate Sodium
Sterile Colistimethate Sodium
Sterile Cytarabine
Sterile Cytarabine
Sterile Dihydrostreptomycin Sulfate
Dihydrostreptomycin Sulfate Injection
Sterile Ifosfamide
Sterile Ifosfamide
Sterile Indocyanine Green
Sterile Indocyanine Green
Sterile Indomethacin Sodium
Sterile Indomethacin Sodium
Sterile Kanamycin Sulfate
Kanamycin Sulfate Injection
Sterile Lincomycin Hydrochloride
Lincomycin Hydrochloride Injection
Sterile Methicillin Sodium
Methicillin Sodium for Injection
Sterile Mezlocillin Sodium
Sterile Mezlocillin Sodium
Sterile Minocycline Hydrochloride
Sterile Minocycline Hydrochloride
Sterile Oxacillin Sodium
Oxacillin Sodium Injection
Oxacillin Sodium for Injection
Sterile Oxytetracycline
Sterile Oxytetracycline Hydrochloride
Oxytetracycline Hydrochloride for Injection
Sterile Penicillin G Potassium
Sterile Penicillin G Potassium
Sterile Penicillin G Sodium
Sterile Penicillin G Sodium

NF 18 New Title

NF 18 Former Title

Betadex
Cellulose
Hypromellose Phthalate

Beta Cyclodextrin
Cellulose Acetate Phthalate
Hydroxypropyl Methylcellulose Phthalate

The following title changes are official January 1, 2000:

USP 23 New Title	USP 23 Former Title
Ceftazidime	Sterile Ceftazidime
Chloramphenicol	Sterile Chloramphenicol
Chloramphenicol Sodium Succinate	Sterile Chloramphenicol Sodium Succinate
Chloramphenicol Sodium Succinate for Injection	Sterile Chloramphenicol Sodium Succinate
Floxuridine	Sterile Floxuridine
Floxuridine for Injection	Sterile Floxuridine
Gentamicin Sulfate	Sterile Gentamicin Sulfate
Gentamicin Injection	Gentamicin Sulfate Injection
Lidocaine Hydrochloride	Sterile Lidocaine Hydrochloride
Succinylcholine Chloride	Sterile Succinylcholine Chloride
Succinylcholine Chloride for Injection	Sterile Succinylcholine Chloride
Tetracaine Hydrochloride	Sterile Tetracaine Hydrochloride
Tetracaine Hydrochloride for Injection	Sterile Tetracaine Hydrochloride
Tetracycline Hydrochloride	Sterile Tetracycline Hydrochloride
Tetracycline Hydrochloride for Injection	Sterile Tetracycline Hydrochloride
Tolbutamide	Sterile Tolbutamide Sodium
Tolbutamide for Injection	Sterile Tolbutamide Sodium
Urea	Sterile Urea
Urea for Injection	Sterile Urea

ANNOTATED LIST

Monographs, General Chapters, Reagents, and Tables Affected by Changes Appearing in This Supplement

Page citations refer to the pages of this Supplement. Note—The absence of a parenthetical term after the section heading denotes a change in the text, as distinguished from a newly added or deleted section.

Monographs (USP 23)

- Capsules Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine;
Dextromethorphan, and Phenylpropanolamine (new), 4501
- Oral Solution Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine;
Dextromethorphan, and Phenylpropanolamine (new), 4503
- Capsules Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine;
Dextromethorphan, and Pseudoephedrine (new), 4504
- Oral Powder Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine;
Dextromethorphan, and Pseudoephedrine (new), 4506
- Oral Solution Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine;
Dextromethorphan, and Pseudoephedrine (new), 4508
- Tablets Containing at Least Three of the Following—
Acetaminophen and Salts of Chlorpheniramine;
Dextromethorphan, and Pseudoephedrine (new), 4509
- Acetaminophen, Dextromethorphan Hydrobromide, Doxylamine Succinate, and Pseudoephedrine Hydrochloride Oral Solution (new), 4511
- Acetaminophen, Diphenhydramine Hydrochloride, and Pseudoephedrine Hydrochloride Tablets (new), 4512
- Acetaminophen and Pseudoephedrine Hydrochloride Tablets, 4513
Dissolution
- Acyclovir Capsules (new), 4514
- Acyclovir for Injection (new), 4514
- Acyclovir Oral Suspension (new), 4515
- Acyclovir Tablets (new), 4515
- Albendazole Tablets (new), 4516
- Albuterol Tablets, 4517
Dissolution
- Altretamine (new), 4517
- Altretamine Capsules (new), 4518
- Aluminum Subacetate Topical Solution, 4518
Definition
- Ammonium Chloride, 4518
Assay
- Ammonium Chloride Injection, 4518
Chloride content
- Ampicillin for Injection, 4518
Dimethylaniline (deleted)
Limit of methylene chloride (deleted)
- Astemizole (new), 4519
- Astemizole Tablets (new), 4519
- Activated Attapulgate, 4520
Powder Fineness
- Colloidal Activated Attapulgate, 4520
Powder Fineness
- Barium Hydroxide Lime, 4520
Size of granules
Hardness
- Betamethasone Dipropionate, 4521
Other impurities (added)
- Betamethasone Valerate, 4521
Other impurities (added)
- Bismuth Subsalicylate, 4521
Limit of free salicylic acid (subsection *Test solution*)
Limit of soluble bismuth (subsection *Procedure*)
Assay for total salicylates (subsection *Procedure*)
- Bretylium Tosylate Injection, 4522
pH
- Caffeine, 4522
Chromatographic purity (added)
Assay
- Calcifediol Capsules, 4523
Disintegration (deleted)
Dissolution
- Calcium and Magnesium Carbonates Oral Suspension (new), 4523
- Calcium Gluconate Injection, 4523
Definition
Labeling
pH
- Calcium Undecylate, 4524
Particle size
- Captropmycin for Injection, 4524
Packaging and storage
pH
- Captopril, 4524
Related compounds (subsections *Resolution solution* and *Chromatographic system*)
- Carbamazepine Tablets, 4524
Dissolution
Assay
- Cefadroxil, 4525
Chromatographic purity (subsection *Procedure*)
- Ceftazidime, 4525
Labeling (added)
- Sterile Ceftazidime, 4526
Title changes
- Cephadrine Capsules, 4526
Definition
Assay
- Cephadrine for Injection, 4526
Definition
USP Reference standards
Assay
- Cephadrine for Oral Suspension, 4527
Definition
USP Reference standards
Assay
- Cephadrine Tablets, 4527
Definition
USP Reference standards
Assay
- Chloral Hydrate Capsules, 4528
Dissolution (added)
- Chloramphenicol, 4528
Labeling (added)
USP Reference standards
Bacterial endotoxins
Sterility
- Sterile Chloramphenicol, 4528
Title changes
- Chloramphenicol Sodium Succinate (new), 4528
- Chloramphenicol Sodium Succinate for Injection (new), 4529
- Sterile Chloramphenicol Sodium Succinate, 4530
Title changes
- Chlorotrianisene Capsules, 4530
Dissolution (added)

- Chlorpheniramine Maleate and Pseudoephedrine Hydrochloride Oral Solution (new), 4530
- Cholecalciferol Solution (new), 4531
- Cholestyramine Resin, 4532
- Exchange capacity*
- Clarithromycin, 4532
- Assay (subsection Chromatographic system)*
- Clindamycin Phosphate, 4533
- Labeling*
- Clindamycin Injection (new), 4533
- Clindamycin for Injection (new), 4533
- Clindamycin Phosphate Injection, 4534
- Title changes*
- Sterile Clindamycin Phosphate, 4534
- Title changes*
- Clobetasol Propionate Cream, 4534
- pH*
- Assay*
- Clofazimine Capsules, 4534
- Disintegration (deleted)*
- Dissolution (added)*
- Clonazepam, 4534
- Definition*
- USP Reference standards*
- Melting range (added)*
- Related compounds*
- Limit of clonazepam related compound C (added)*
- Assay*
- Clonazepam Tablets, 4535
- USP Reference standards*
- Identification*
- Uniformity of dosage units*
- Related compounds*
- Assay*
- Cocaine and Tetracaine Hydrochlorides and Epinephrine Topical Solution (new), 4535
- Colchicine, 4536
- Definition*
- Colistimethate Sodium (new), 4536
- Colistimethate for Injection (new), 4537
- Sterile Colistimethate Sodium, 4537
- Title changes*
- Cortisone Acetate, 4537
- Chromatographic purity (added)*
- Ordinary impurities (deleted)*
- Cupric Chloride, 4538
- Organic volatile impurities*
- Cyclosporine Capsules, 4539
- Disintegration (deleted)*
- Dissolution*
- Cytarabine, 4539
- Labeling (added)*
- USP Reference standards*
- Identification (test B)*
- Other requirements (added)*
- Cytarabine for Injection (new), 4540
- Sterile Cytarabine, 4541
- Title changes*
- Dexbrompheniramine Maleate and Pseudoephedrine Sulfate Oral Solution (new), 4541
- Diazoxide Capsules, 4541
- Dissolution (subsection Medium)*
- Diclofenac Sodium Delayed-release Tablets, 4542
- Assay (subsections Assay preparation and Procedure)*
- Diflorasone Diacetate, 4543
- Other impurities (added)*
- Dihydrostreptomycin Sulfate, 4543
- Labeling*
- USP Reference standards*
- Other requirements (added)*
- Dihydrostreptomycin Injection (new), 4543
- Dihydrostreptomycin Sulfate Injection, 4543
- Title changes*
- Sterile Dihydrostreptomycin Sulfate, 4543
- Title changes*
- Dihydroxyacetone (new), 4543
- Diltiazem Hydrochloride Extended-release Capsules, 4544
- Drug release*
- Diphenhydramine and Pseudoephedrine Capsules, 4545
- Dissolution*
- Dobutamine Hydrochloride, 4545
- Assay*
- Dobutamine Injection, 4545
- Assay*
- Dobutamine for Injection, 4546
- Assay*
- Docusate Potassium Capsules, 4546
- Dissolution (added)*
- Doxylamine Succinate Tablets, 4546
- Assay*
- Dronabinol Capsules, 4547
- Dissolution (added)*
- Dydrogesterone Tablets, 4547
- Dissolution*
- Multiple Electrolytes Injection Type 1, 4547
- Assay for chloride*
- Erythromycin, 4548
- Assay*
- Erythromycin Estolate Capsules, 4548
- Disintegration (added)*
- Estradiol Cypionate, 4549
- Other impurities (added)*
- Ethchlorvynol Capsules, 4549
- Dissolution (added)*
- Etoposide, 4549
- Related compounds (subsections Standard solution and System suitability solution)*
- Etoposide Capsules, 4550
- Dissolution*
- Floxuridine, 4550
- Labeling (added)*
- Other requirements*
- Floxuridine for Injection (new), 4550
- Sterile Floxuridine (new), 4551
- Title changes*
- Fludrocortisone Acetate, 4551
- Other impurities (added)*
- Fludrocortisone Acetate Tablets, 4551
- Disintegration (deleted)*
- Dissolution*
- Fludeoxyglucose F 18 Injection, 4551
- Specific activity*
- USP Reference standards*
- Radionuclide identification*
- Radiochemical purity*
- Other requirements*
- Fluoxymesterone, 4552
- Other impurities (added)*
- Fluphenazine Hydrochloride Elixir, 4552
- Alcohol content*
- Folic Acid Tablets, 4552
- USP Reference standards*
- Assay*
- Fructose and Sodium Chloride Injection, 4552
- Assay for sodium chloride*
- Gentamicin Sulfate, 4553
- Labeling (added)*
- USP Reference standards*
- Other requirements*
- Gentamicin Sulfate Cream, 4553
- Identification*
- Gentamicin Uterine Infusion, 4553
- Identification*
- Sterility*
- Gentamicin Injection (new), 4553
- Gentamicin Sulfate Injection, 4554
- Title changes*
- Gentamicin Sulfate Ointment, 4554
- Identification*
- Gentamicin Sulfate Ophthalmic Ointment, 4554
- Identification*
- Gentamicin Sulfate Ophthalmic Solution, 4554
- Other requirements*
- Sterile Gentamicin Sulfate, 4554
- Title changes*

- Guanadrel Sulfate Tablets, 4554
Dissolution
 Guanfacine Hydrochloride, 4555
Identification (test B)
Related compounds (subsections *Standard solutions* and *Procedure*)
 Hydralazine Hydrochloride Oral Solution (new), 4556
 Hydrocortisone, 4556
Chromatographic purity (subsections *Diluting solution*, *Standard solution*, and *Test solution*)
 Hydrocortisone Butyrate, 4557
Other impurities (added)
 Hydroxychloroquine Sulfate, 4557
Identification (test B)
 Hydroxyzine Hydrochloride, 4557
Assay
 Ifosfamide, 4558
Labeling (added)
USP Reference standards
Other requirements (added)
 Ifosfamide for Injection (new), 4558
 Sterile Ifosfamide, 4558
Title changes
 Indapamide Tablets, 4558
Dissolution
 Indocyanine Green, 4559
Labeling (added)
USP Reference standards
Other requirements (added)
 Indocyanine Green for Injection (new), 4559
 Sterile Indocyanine Green, 4559
Title changes
 Indomethacin Sodium, 4559
Labeling (added)
Identification (test A)
Other requirements (added)
 Indomethacin for Injection (new), 4559
 Sterile Indomethacin Sodium, 4560
Title changes
 Iopamidol, 4560
Limit of free iodide
 Iopamidol Injection, 4561
Limit of free iodide
 Ioxilan (new), 4562
 Ioxilan Injection (new), 4563
 Kanamycin Sulfate, 4564
Labeling (added)
USP Reference standards
Other requirements (added)
 Kanamycin Injection (new), 4564
 Kanamycin Sulfate Injection, 4564
Title changes
 Sterile Kanamycin Sulfate, 4564
Title changes
 Ketoprofen, 4564
Chromatographic purity
 Levamisole Hydrochloride Tablets, 4565
Assay (subsections *Standard preparation*, *Resolution solution*, *Assay preparation*, and *Procedure*)
 Levocarnitine Injection (new), 4565
 Levonorgestrel and Ethinyl Estradiol Tablets, 4566
Dissolution
 Lidocaine Hydrochloride, 4566
Labeling (added)
USP Reference standards
Other requirements (added)
 Sterile Lidocaine Hydrochloride, 4567
Title changes
 Lincomycin Hydrochloride, 4567
Labeling (added)
Depressor substances
Other requirements
 Lincomycin Hydrochloride Injection, 4567
Title changes
 Lincomycin Injection (new), 4567
 Sterile Lincomycin Hydrochloride, 4567
Title changes
 Mafenide Acetate, 4567
Loss on drying (deleted)
Water
 Magnesium Carbonate and Citric Acid for Oral Solution (new), 4567
 Magnesium Citrate for Oral Solution (new), 4568
 Mebendazole Tablets, 4568
Disintegration (deleted)
Dissolution
 Melfalan Tablets, 4569
Disintegration (deleted)
Dissolution
 Mephobarbital Tablets, 4569
Dissolution (subsections *Medium* and *Procedure*)
 Mesalamine, 4569
Clarity of solution
 Methazolamide, 4570
Definition
Assay
 Methazolamide Tablets, 4571
Definition
Assay
 Methicillin Sodium (new), 4571
 Meticillin for Injection (new), 4572
 Methicillin Sodium for Injection, 4573
Title changes
 Sterile Methicillin Sodium, 4573
Title changes
 Methotrimoprazine Injection, 4573
Assay
 Methylgonovine Maleate, 4573
Identification
Assay (subsection *Chromatographic system*)
 Methylprednisolone Acetate, 4573
Chromatographic purity (added)
 Methylprednisolone Hemisuccinate, 4574
Other impurities (added)
 Methyltestosterone, 4574
Other impurities (added)
 Metronidazole Gel, 4574
Identification (test A)
 Mezlocillin Sodium (new), 4574
 Mezlocillin for Injection (new), 4575
 Sterile Mezlocillin Sodium, 4576
Title changes
 Minocycline Hydrochloride, 4576
Labeling (added)
USP Reference standards
Other requirements (added)
 Minocycline for Injection (new), 4576
 Sterile Minocycline Hydrochloride, 4576
Title changes
 Minoxidil Topical Solution (new), 4577
 Monensin, 4577
Packaging and storage
Limit of related compounds activity
 Monensin Granulated, 4578
Packaging and storage
Limit of related compounds activity
 Monensin Premix, 4578
Packaging and storage
 Monensin Sodium, 4579
Packaging and storage
Limit of related compounds activity
 Moricizine Hydrochloride, 4580
Assay (subsection *Chromatographic system*)
 Naltrexone Hydrochloride (new), 4581
 Naltrexone Hydrochloride Tablets (new), 4582
 Nandrolone Decanoate, 4582
Chromatographic purity
 Narasin Granular (new), 4583
 Narasin Premix (new), 4584
 Nicotine Transdermal System, 4584
Assay (subsection *Procedure*)
 Nitrofurazone, 4586
Limit of 5-nitro-2-furfuraldehyde (subsection *Procedure*)
 Diluted Nitroglycerin, 4586

- Definition**
Oxacillin Sodium, 4587
Labeling (added)
USP Reference standards
Other requirements (added)
Oxacillin Injection (new), 4587
Oxacillin for Injection (new), 4588
Oxacillin Sodium Injection (new), 4588
Oxacillin Sodium for Injection, 4588
Title changes
Sterile Oxacillin Sodium, 4588
Title changes
Oxytetracycline, 4588
Labeling (added)
USP Reference standards
Other requirements (added)
Sterile Oxytetracycline, 4589
Title changes
Oxytetracycline Hydrochloride, 4589
Labeling (added)
USP Reference standards
Other requirements (added)
Oxytetracycline for Injection (new), 4590
Oxytetracycline Hydrochloride for Injection, 4590
Title changes
Sterile Oxytetracycline Hydrochloride, 4590
Title changes
Penicillin G Benzathine and Penicillin G Procaine Injectable Suspension, 4590
Definition
Labeling (added)
USP Reference standards
Crystallinity (added)
Limit of soluble penicillin G and procaine (added)
Other requirements
Penicillin G Potassium, 4592
Labeling (added)
Penicillin G content (deleted)
Other requirements (added)
Penicillin G Potassium for Injection, 4592
Definition
Penicillin G content (deleted)
Assay (subsection *Procedure*)
Sterile Penicillin G Potassium, 4593
Title changes
Penicillin G Sodium (new), 4593
Penicillin G Sodium for Injection, 4593
Definition
Sterility (added)
Other requirements
Assay (subsection *Procedure*)
Sterile Penicillin G Sodium, 4594
Title changes
Penicillin V for Oral Suspension, 4594
Identification
Penicillin V Tablets, 4594
Identification
Penicillin V Potassium for Oral Solution, 4594
Identification
Penicillin V Potassium Tablets, 4594
Identification
Perphenazine Oral Solution, 4594
Limit of perphenazine sulfoxide
Assay
Phenylpropanolamine Hydrochloride Capsules (new), 4595
Phenylpropanolamine Hydrochloride Oral Solution (new), 4595
Phenylpropanolamine Hydrochloride Tablets (new), 4595
Phenytoin Oral Suspension, 4596
USP Reference standards (added)
Assay
Piperazine Citrate Tablets, 4596
Dissolution
Potassium Chloride Extended-release Tablets, 4596
Assay
Potassium Chloride in Dextrose Injection, 4597
Assay for potassium chloride
Potassium Chloride in Dextrose and Sodium Chloride Injection, 4597
Assay for chloride
Potassium Chloride in Sodium Chloride Injection, 4597
Assay for chloride
Prednisolone, 4597
Other impurities (added)
Probenecid and Colchicine Tablets, 4598
Dissolution (subsection *Medium*)
Procainamide Hydrochloride Extended-release Tablets, 4598
Drug release
Prochlorperazine Edisylate Injection, 4599
Assay
Procyclidine Hydrochloride Tablets, 4599
Dissolution
Progesterone, 4599
Other impurities (added)
Progesterone Intrauterine Contraceptive System, 4599
Drug-release pattern
Pseudoephedrine Hydrochloride Tablets, 4600
Dissolution
Pseudoephedrine Hydrochloride Extended-release Tablets (new), 4600
Pyridostigmine Bromide Tablets, 4601
Dissolution (subsections *Time and Tolerances*)
Ribavirin, 4601
Specific rotation
Rifampin Oral Suspension (new), 4601
Rimexolone (new), 4602
Rimexolone Ophthalmic Suspension (new), 4602
Roxarsone (new), 4602
Selenomethionine (new), 4603
Simvastatin Tablets (new), 4604
Sodium Bicarbonate, 4605
Sulfate (deleted)
Limit of sulfur compounds
Sodium Chloride, 4605
Aluminum
Sodium Hypochlorite Topical Solution (new), 4606
Sodium Nitroprusside, 4607
Identification 1 (test C)
Spiroolactone Tablets, 4607
Assay (subsection *Assay preparation*)
Succinylcholine Chloride, 4607
Labeling (added)
USP Reference standards
Other requirements (added)
Succinylcholine Chloride for Injection (new), 4607
Sterile Succinylcholine Chloride, 4608
Title changes
Sulfamethazine Granulated, 4608
Packaging and storage
Sulfipyrazole Capsules, 4608
Dissolution (subsection *Medium*)
Sulfipyrazole Tablets, 4608
Dissolution (subsection *Medium*)
Technetium Tc 99m Tetrofosmin Injection (new), 4608
Terbutaline Sulfate Tablets, 4609
Dissolution
Testolactone, 4609
Other impurities (added)
Testosterone Cypionate, 4609
Other impurities (added)
Tetracaine Hydrochloride, 4609
Labeling (added)
USP Reference standards
Identification (test A)
Other requirements (added)
Tetracaine Hydrochloride for Injection (new), 4609
Sterile Tetracaine Hydrochloride, 4610
Title changes
Tetracycline Hydrochloride, 4610
Labeling (added)
USP Reference standards
Other requirements (added)
Tetracycline Hydrochloride for Injection, 4611
Definition
Depressor substances (added)

Particulate matter
Other requirements
 Sterile Tetracycline Hydrochloride, 4611
 Title changes
 Tetracycline Hydrochloride Ophthalmic Suspension, 4611
 Definition
 Theophylline Extended-release Capsules, 4611
 Drug release
 Thiactetarsamide, 4613
 Loss on drying
 Thiethylperazine Malate, 4613
 Organic volatile impurities
 Thiopental Sodium, 4613
 Identification (test C)
 Thiostrepton, 4614
 Identification
 Tiletamine Hydrochloride (new), 4614
 Tiletamine and Zolazepam for Injection (new), 4614
 Tilmicosin, 4615
 Packaging and storage
 Tilmicosin Injection, 4616
 Packaging and storage
 Tolazamide, 4617
 Other impurities (added)
 Tolbutamide, 4617
 Labeling (added)
 USP Reference standards
 Other requirements
 Tolbutamide for Injection (new), 4617
 Sterile Tolbutamide Sodium (new), 4618
 Title changes
 Triamcinolone Diacetate, 4618
 Loss on drying (deleted)
 Water (added)
 Triclosan (new), 4618
 Triprolidine and Pseudoephedrine Hydrochlorides Tablets, 4620
 Dissolution
 Urea, 4620
 Labeling (added)
 USP Reference standards
 Other requirements
 Urea for Injection (new), 4620
 Sterile Urea, 4620
 Title changes
 Valproic Acid, 4620
 USP Reference standards
 Identification
 Chromatographic purity
 Assay
 Valproic Acid Capsules, 4621
 Dissolution
 Warfarin Sodium Tablets, 4621
 Identification (test C)
 Bacteriostatic Water for Injection, 4622
 Other requirements
 Zolazepam Hydrochloride (new), 4622

General Chapters

General Tests and Assays

GENERAL REQUIREMENTS FOR TESTS AND ASSAYS

- (11) USP Reference standards, 4623
 USP 5-Acetamido-3-amino-2,4,6-triiodobenzoic Acid RS
 USP Alfentanil Hydrochloride RS
 USP Allopurinol Related Compound A RS
 USP 3-Amino-4-carboxamidopyrazole Hemisulfate RS
 USP 2-Amino-2'-chloro-5-nitrobenzophenone RS
 USP Alretamine RS
 USP Amrinone RS
 USP Apigenin-7-O-glucoside RS
 USP Astemizole RS
 USP Baclofen Related Compound A RS
 USP Cefotiam Hydrochloride RS
 USP Cephapirin Benzathine RS
 USP Chlordiazepoxide Related Compound A RS

USP 7-Chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one
 4-Oxide RS
 USP (o-Chlorophenyl)diphenylmethanol RS
 USP 4-(4-Chlorophenyl)-2-pyrrolidone RS
 USP Cholestyramine Resin RS
 USP Clavam-2-Carboxylate Potassium RS
 USP Clindamycin Phosphate RS
 USP Clobetasol Propionate RS
 USP Clonazepam Related Compound B RS
 USP Clostrazole Related Compound A RS
 USP Diatrizoic Acid Related Compound A RS
 USP Diazepam Related Compound A RS
 USP Dihydroxyacetone RS
 USP Dobutamine Hydrochloride RS
 USP Erythromycin RS
 USP Etoposide RS
 USP Fludeoxyglucose RS
 USP Fluoxetine Related Compound B RS
 USP Oriental Ginseng Extract RS
 USP Glycerin RS
 USP Hyperoside RS
 USP Iohexol RS
 USP Ioxilan RS
 USP Ioxilan Related Compound A RS
 USP Lactase RS
 USP Lactulose RS
 USP Methylamino-5-chlorobenzophenone RS
 USP Nafifine Hydrochloride RS
 USP Naltrexone RS
 USP Naltrexone Related Compound A RS
 USP Ofloxacin RS
 USP Parbenzazole RS
 USP Parthenolide RS
 USP Particle Count RS
 USP Phenylpropanolamine Bitartrate RS
 USP Piperacillin RS
 USP Negative Control Plastic RS
 USP Poloxalene RS
 USP Polyethylene Terephthalate G Copolyester RS
 USP Pyridostigmine Bromide RS
 USP Quazepam RS
 USP Quazepam Related Compound A RS
 USP Quercetin RS
 USP Rimexolone RS
 USP Roxarsone RS
 USP Rutin RS
 USP Selenomethionine RS
 USP Simvastatin RS
 USP Sulbactam RS
 USP Thiostrepton RS
 USP Tiletamine Hydrochloride RS
 USP Alpha Tocopherol RS
 USP Triclosan RS
 USP Triclosan Related Compound A RS
 USP Triclosan Related Compound B RS
 USP Tylosin RS
 USP Valerianic Acid RS
 USP Powdered Valerian RS
 USP Valproic Acid Related Compound A RS
 USP Zolazepam Hydrochloride RS

CHEMICAL TESTS AND ASSAYS

IDENTIFICATION TESTS

- (191) Identification Tests—General, 4634
 Sodium

OTHER TESTS AND ASSAYS

- (401) Fats and Fixed Oils, 4636
 Hydroxyl Value (subsection Pyridine-Acetic Anhydride Reagent)
 Iodine Value (subsection Procedure under subhead Method II)
 Saponification Value (subsection Procedure)
 (561) Vegetable Drugs, 4640
 Methods of Analysis (subhead Test for Aflatoxins)
 General Methods for Pesticide Residues Analysis (added)
 Test for Pesticides (added)

PHYSICAL TESTS AND DETERMINATIONS

- (611) Alcohol Determination, 4646
Method—Distillation Method
- (621) Chromatography, 4647
High-Pressure Liquid Chromatography
System Suitability
- (661) Containers, 4654
Chemical Resistance—Glass Containers (subsection Reagents)
- (701) Disintegration, 4659
Apparatus
Procedure
- (711) Dissolution, 4660
Apparatus 1
Apparatus 2
Dissolution Medium (Footnote 3)
Procedure for Capsules, Uncoated Tablets, and Plain Coated Tablets
Interpretation
- (721) Distilling Range, 4662
Method II (subsection Procedure)
- (724) Drug Release, 4663
Figures 1 and 5
- (811) Powder Fineness, 4670
Introduction
Table 1 (deleted)
Table 2 (deleted)
Sieves for Pharmacopoeial Testing
Method for Determining Uniformity of Fineness (deleted)
Classification of Powder Fineness (added)
- (846) Specific Surface Area, 4671
Introduction

General Information

- (1051) Cleaning Glass Apparatus (new), 4674
- (1161) Pharmacy Compounding Practices, 4674
Introduction
Stability of compounded Preparations (subhead Stability Criteria and Beyond-use Dating)
Ingredient Selection and Calculations (subheads Sources and Calculations)
Checklist for Acceptable Strength, Quality, and Purity
Compounded Dosage Forms
Compounding Process
- (1216) Tablet Friability, 4673

Reagents, Indicators, and Solutions

REAGENT SPECIFICATIONS

- 3-Acetylthio-2-methylpropanoic Acid (new), 4679
- Amaranth (new), 4679
- Butyric Acid (new), 4679
- Calcium Carbonate, Precipitated, 4679
Reagent deleted
- 1-Chloronaphthalene (new), 4679
- 4-Chlorophenol (new), 4679
- 2,8-Dichlorodibenzofuran (new), 4679
- 2,4-Dichlorophenol (new), 4679
- Ethanesulfonic Acid (new), 4679
- Mineral Acid (new), 4679
- Nonanoic Acid (new), 4679
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, ¹³C-labeled (new), 4679
- 2,3,7,8-Tetrachlorodibenzofuran, ¹³C-labeled (new), 4679
- 2,4,8-Trichlorodibenzofuran (new), 4679
- Valeric Acid (new), 4680

TEST SOLUTIONS

- Amaranth TS (new), 4680
- Brilliant Blue G TS (new), 4680
- Gastric Fluid, Simulated, TS, 4680
- pH 4.7 Phenol Red TS (new), 4680
- Iodide-free Starch TS (new), 4680

REAGENT FOOTNOTES

Footnote 89 (added) 4680

Reference Tables

Description and Relative Solubility of USP and NF Articles, 4681

Alfretamine (new)
Calcium Carbonate, Precipitated
Dihydroxyacetone (new)
Ioxilan (new)
Ioxilan Injection (new)
Mafenide Acetate (new)
Narazin (new)
Rimexolone (new)
Roxarsone (new)
Tiletamine Hydrochloride (new)
Triclosan (new)
Zolazepam Hydrochloride (new)

Intrinsic Viscosity Table, 4682

Nutritional Supplements

Monographs (USP 23)

Oil- and Water-soluble Vitamins with Minerals Tablets, 4684
Assay for vitamin A

General Chapters

- (2040) Disintegration and Dissolution of Nutritional Supplements, 4696
Dissolution
Dissolution Conditions for Folic Acid
Dissolution Conditions for Index Vitamins and Index Minerals (subsection Procedures)

Monographs (NF 18)

- Beta Cyclodextrin, 4698
Title changes
- Betadex (new), 4699
- Cellulose (new), 4699
- Microcrystalline Cellulose, 4699
Conductivity
- Cellulose Acetate Phthalate (new), 4700
Title changes
- Chamomile (new), 4700
- Dimethicone (new), 4702
Definition
Assay
- Hard Fat, 4703
Labeling
Melting range
- Feverfew (new), 4703
- Powdered Feverfew (new), 4704
- Ginger, 4704
Identification
Alcohol-soluble extractives
Volatile oil content
- Ginkgo (new), 4705
- Oriental Ginseng (new), 4706
- Powdered Oriental Ginseng (new), 4707
- Hydroxypropyl Methylcellulose Phthalate, 4708
Title changes
- Hypromellose Phthalate (new), 4708
- Lactitol (new), 4708
- St. John's Wort (new) 4709
- Powdered St. John's Wort (new), 4710
- Saw Palmetto (new), 4710
- Sodium Lauryl Sulfate, 4711
Identification (test A)
- Sugar Spheres 4712
Particle size
- Vitamin E Polyethylene Glycol Succinate 4712